Pfizer eyes Covid vaccine for all variants before 2023 | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Get the Paper
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Wednesday
July 23, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Get the Paper
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
WEDNESDAY, JULY 23, 2025
Pfizer eyes Covid vaccine for all variants before 2023

Coronavirus chronicle

BSS/AFP
14 April, 2022, 10:45 am
Last modified: 14 April, 2022, 10:51 am

Related News

  • US FDA approves Pfizer's drug for rare bleeding disorder
  • Pfizer cuts earnings outlook on lower Covid-19 drug sales
  • Pfizer's updated Covid shot effective against 'Eris' variant in mice study
  • US FDA approves Pfizer's blood cancer therapy
  • Tornado damage to Pfizer plant unlikely to cause major drug supply shortages: FDA

Pfizer eyes Covid vaccine for all variants before 2023

BSS/AFP
14 April, 2022, 10:45 am
Last modified: 14 April, 2022, 10:51 am
A woman holds a small bottle labeled with a "Coronavirus Covid-19 Vaccine" sticker and a medical syringe in front of displayed Pfizer logo in this illustration taken, October 30, 2020. REUTERS/Dado Ruvic/File Photo
A woman holds a small bottle labeled with a "Coronavirus Covid-19 Vaccine" sticker and a medical syringe in front of displayed Pfizer logo in this illustration taken, October 30, 2020. REUTERS/Dado Ruvic/File Photo

A Covid-19 vaccine effective against multiple variants is possible before the end of 2022, the head of US pharmaceutical giant Pfizer said Wednesday.

Chairman Albert Bourla said the firm was also working on producing a vaccine that could provide good protection for a whole year, meaning people would come back annually for boosters, as with influenza shots.

"I hope, clearly by autumn... that we could have a vaccine" that worked against not only the dominant Omicron but all known variants, he said.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

"It is a possibility that we have it by then. It is not a certainty," he told a media briefing organised by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) big pharma lobby group.

The Pfizer-BioNTech vaccine is one of the most effective against Covid-19.

Though, like other jabs, it has seen waning effectiveness against the now-dominant Omicron variant of the virus, it still offers strong protection against serious disease, hospitalisation and death.

IFPMA director general Thomas Cueni said the world had to learn to live with the virus that causes Covid-19 disease, saying: "We are beyond the time when you can eradicate SARS-CoV-2."

Bourla said there was a risk of vaccine fatigue, predicting that few people who have so far declined the chance to be vaccinated would change their minds, and suggesting that fewer people would come back for fourth doses than came forward for a third, booster dose.

"What the world really needs is a vaccine that will last a year. I think this is what will become the optimal public health solution," he said.

"It's way more easy to be administered and have the population be compliant with that.

"It is very challenging, technically, to do it with this virus -- but we are working on it."

IP waiver plan blasted

The World Health Organization is aware of 153 Covid-19 vaccines that have been in clinical development -- tested on humans -- and 196 in pre-clinical development.

But so far, the UN health agency has only authorised eight vaccines and versions thereof: those made by Pfizer-BioNTech, AstraZeneca, Janssen, Moderna, Sinovac, Sinopharm, Bharat Biotech and Novavax.

The IFPMA briefing condemned suggestions that intellectual property rights on Covid-19 vaccines should be temporarily lifted during the pandemic, in a bid to increase production.

"I'm stunned that the proposed IP waiver is still debated while supplies are far outstripping demand," said Cueni.

With more than a billion vaccine doses being produced every month, Eli Lilly chairman David Ricks called it "a solution looking for a problem", while Bourla branded the idea "insane".

In a later WHO press conference, the UN health agency's chief scientist Soumya Swaminathan said the vaccine supply situation had dramatically improved in recent months.

The problem, she said, was more one of logistics and getting doses into arms in countries, especially in Africa, where only 13 percent have been fully jabbed.

"We are able to now supply as many doses as countries want, on demand, to them. The issue now really is on delivery," she said.

Top News / World+Biz

Pfizer / Pfizer Inc / Pfizer Covid-19 Vaccine / Pfizer coronavirus vaccine / Pfizer COVID vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Photo: CA Press Wing
    Stronger stance needed on maintaining law and order: Political parties to CA
  • Volunteers collect and gather parts of the wrecked plane from the Milestone School and College grounds on Tuesday, a day after the devastating aircraft crash. Photo: Mehedi Hasan/TBS
    Grief, angst and anger: The unbearable toll of Milestone crash
  • Photo: Syed Zakir Hossain/TBS
    Secretariat protest: 75 injured in police-protester clash over edu adviser's resignation for delaying HSC rescheduling

MOST VIEWED

  • Screengrab/Video collected from Facebook
    CCTV footage shows how Air Force jet nosedived after technical malfunction
  • ISPR clarifies crashed plane was battle aircraft, not training jet
    ISPR clarifies crashed plane was battle aircraft, not training jet
  • The jet plane charred after crash on 21 July at the Milestone school premises. Photo: Mehedi Hasan/TBS
    Milestone plane crash: Death toll rises to 31 as nine more succumb to injuries
  • Students and police clash at Milestone School and College on 22 July 2025. Photo: TBS
    Protesting Milestone students clash with police, besiege law and education advisers
  • Photo: Syed Zakir Hossain/TBS
    Secretariat protest: 75 injured in police-protester clash over edu adviser's resignation for delaying HSC rescheduling
  • Aerial view of the Milestone school premises where the crash took place on 21 July. Photo: Olid Ebna Shah/ TBS
    ‘Why here?’: Concerns expressed over airbase inside city

Related News

  • US FDA approves Pfizer's drug for rare bleeding disorder
  • Pfizer cuts earnings outlook on lower Covid-19 drug sales
  • Pfizer's updated Covid shot effective against 'Eris' variant in mice study
  • US FDA approves Pfizer's blood cancer therapy
  • Tornado damage to Pfizer plant unlikely to cause major drug supply shortages: FDA

Features

Photo: Mehedi Hasan/TBS

Aggrieved nation left with questions as citizens rally to help at burn institute

13h | Panorama
Photo: TBS

Mourning turns into outrage as Milestone students seek truth and justice

7h | Panorama
Illustration: TBS

Uttara, Jatrabari, Savar and more: The killing fields that ran red with July martyrs’ blood

1d | Panorama
Despite all the adversities, girls from the hill districts are consistently pushing the boundaries to earn repute and make the nation proud. Photos: TBS

Ghagra: Where dreams rise from dust for Bangladesh women's football

2d | Panorama

More Videos from TBS

What information did the director of the NBPSI give about the admitted patients?

What information did the director of the NBPSI give about the admitted patients?

6h | TBS Today
What is discussed at the Chief Advisor's meeting?

What is discussed at the Chief Advisor's meeting?

6h | TBS Today
Two advisors and press secretary were blocked at Milestone for 8 hours

Two advisors and press secretary were blocked at Milestone for 8 hours

6h | TBS Today
Chief advisor's meeting with 4 parties; what was discussed?

Chief advisor's meeting with 4 parties; what was discussed?

7h | TBS Today
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net